Home LiteratureArticle Details
PMID: 29670256 Published · epublish English Journal Article Research Support, Non-U.S. Gov't

Deviations of the immune cell landscape between healthy liver and hepatocellular carcinoma.

Scientific reports ·Vol. 8 ·No. 1 ·2018-00-18 ·Pages 6220

Rohr-Udilova N, Klinglmüller F, Schulte-Hermann R, Stift J, Herac M, Salzmann M, Finotello F, Timelthaler G, Oberhuber G, Pinter M, Reiberger T, Jensen-Jarolim E, Eferl R, Trauner M

Abstract

Tumor-infiltrating immune cells are highly relevant for prognosis and identification of immunotherapy targets in hepatocellular carcinoma (HCC). The recently developed CIBERSORT method allows immune cell profiling by deconvolution of gene expression microarray data. By applying CIBERSORT, we assessed the relative proportions of immune cells in 41 healthy human livers, 305 HCC samples and 82 HCC adjacent tissues. The obtained immune cell profiles provided enumeration and activation status of 22 immune cell subtypes. Mast cells were evaluated by immunohistochemistry in ten HCC patients. Activated mast cells, monocytes and plasma cells were decreased in HCC, while resting mast cells, total and naïve B cells, CD4+ memory resting and CD8+ T cells were increased when compared to healthy livers. Previously described S1, S2 and S3 molecular HCC subclasses demonstrated increased M1-polarized macrophages in the S3 subclass with good prognosis. Strong total immune cell infiltration into HCC correlated with total B cells, memory B cells, T follicular helper cells and M1 macrophages, whereas weak infiltration was linked to resting NK cells, neutrophils and resting mast cells. Immunohistochemical analysis of patient samples confirmed the reduced frequency of mast cells in human HCC tumor tissue as compared to tumor adjacent tissue. Our data demonstrate that deconvolution of gene expression data by CIBERSORT provides valuable information about immune cell composition of HCC patients.

MeSH Terms
Adaptive Immunity Carcinoma, Hepatocellular/immunology,pathology Case-Control Studies Cellular Microenvironment/immunology Humans Immunity, Innate Immunophenotyping Liver/cytology,immunology Liver Neoplasms/immunology,pathology Lymphocyte Subsets/immunology,metabolism,pathology Lymphocytes, Tumor-Infiltrating/immunology,metabolism,pathology Tumor Microenvironment/immunology
Authors & Affiliations
14 authors, click to expand affiliations / ORCID
Rohr-Udilova Nataliya
Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Waehringer Guertel 18-20, A-1090, Vienna, Austria. nataliya.rohr-udilova@meduniwien.ac.at.
Klinglmüller Florian
Centre for Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna, Spitalgasse 23, A-1090, Vienna, Austria.
Schulte-Hermann Rolf
Institute of Cancer Research, Internal Medicine I, Medical University of Vienna and Comprehensive Cancer Center (CCC), Borschkegasse 8a, A-1090, Vienna, Austria.
Stift Judith
Clinical Institute of Pathology, Medical University of Vienna, Waehringer Guertel 18-20, A-1090, Vienna, Austria.
Herac Merima
Clinical Institute of Pathology, Medical University of Vienna, Waehringer Guertel 18-20, A-1090, Vienna, Austria.
Salzmann Martina
Institute of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.
Finotello Francesca ORCID
Division of Bioinformatics, Biocenter, Medical University of Innsbruck, Innrain 80-82, 6020, Innsbruck, Austria.
Timelthaler Gerald
Clinical Institute of Pathology, Medical University of Vienna, Waehringer Guertel 18-20, A-1090, Vienna, Austria.
Oberhuber Georg
Clinical Institute of Pathology, Medical University of Vienna, Waehringer Guertel 18-20, A-1090, Vienna, Austria.
Pinter Matthias
Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Waehringer Guertel 18-20, A-1090, Vienna, Austria.
Reiberger Thomas ORCID
Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Waehringer Guertel 18-20, A-1090, Vienna, Austria.
Jensen-Jarolim Erika
Institute of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria. | Comparative Medicine, The Interuniversity Messerli Research Institute of the University of Veterinary Medicine Vienna, Medical University Vienna and University Vienna, Vienna, Austria.
Eferl Robert
Clinical Institute of Pathology, Medical University of Vienna, Waehringer Guertel 18-20, A-1090, Vienna, Austria.
Trauner Michael
Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Waehringer Guertel 18-20, A-1090, Vienna, Austria.
References (38)
38 references, click to expand
  1. Immune checkpoints and their inhibition in cancer and infectious diseases.
    Eur J Immunol. 2017 May;47(5):765-779 PMID: 28393361
  2. Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy.
    J Immunother Cancer. 2017 May 16;5:44 PMID: 28515944
  3. Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice.
    Hepatology. 2014 Apr;59(4):1435-47 PMID: 24242874
  4. Unique early gene expression patterns in human adult-to-adult living donor liver grafts compared to deceased donor grafts.
    Am J Transplant. 2009 Apr;9(4):758-72 PMID: 19353763
  5. Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data.
    Elife. 2017 Nov 13;6:null PMID: 29130882
  6. Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases.
    Nat Rev Drug Discov. 2007 May;6(5):373-90 PMID: 17464296
  7. Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma.
    Hepatology. 2007 Apr;45(4):938-47 PMID: 17393520
  8. PD-1 blockade induces responses by inhibiting adaptive immune resistance.
    Nature. 2014 Nov 27;515(7528):568-71 PMID: 25428505
  9. Gene expression in fixed tissues and outcome in hepatocellular carcinoma.
    N Engl J Med. 2008 Nov 6;359(19):1995-2004 PMID: 18923165
  10. IL17A gene polymorphisms, serum IL-17A and IgE levels, and hepatocellular carcinoma risk in patients with chronic hepatitis B virus infection.
    Mol Carcinog. 2014 Jun;53(6):447-57 PMID: 23280722
  11. Patterns of Immune Infiltration in Breast Cancer and Their Clinical Implications: A Gene-Expression-Based Retrospective Study.
    PLoS Med. 2016 Dec 13;13(12 ):e1002194 PMID: 27959923
  12. xCell: digitally portraying the tissue cellular heterogeneity landscape.
    Genome Biol. 2017 Nov 15;18(1):220 PMID: 29141660
  13. Wide gene expression profiling of ischemia-reperfusion injury in human liver transplantation.
    Liver Transpl. 2007 Jan;13(1):99-113 PMID: 17192907
  14. Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma.
    Gut. 2017 Feb;66(2):342-351 PMID: 26669617
  15. A small molecule polyamine oxidase inhibitor blocks androgen-induced oxidative stress and delays prostate cancer progression in the transgenic adenocarcinoma of the mouse prostate model.
    Cancer Res. 2009 Oct 1;69(19):7689-95 PMID: 19773450
  16. An orthotopic mouse model of hepatocellular carcinoma with underlying liver cirrhosis.
    Nat Protoc. 2015 Aug;10(8):1264-74 PMID: 26203823
  17. The predictive value of centre tumour CD8⁺ T cells in patients with hepatocellular carcinoma: comparison with Immunoscore.
    Oncotarget. 2015 Nov 3;6(34):35602-15 PMID: 26415232
  18. Mast cells as targets for immunotherapy of solid tumors.
    Mol Immunol. 2015 Jan;63(1):113-24 PMID: 24698842
  19. Gender-related differences in polyamine oxidase activity in rat tissues.
    Amino Acids. 1999;17(2):139-48 PMID: 10524272
  20. Immunological and regenerative aspects of hepatic mast cells in liver allograft rejection and tolerance.
    PLoS One. 2012;7(5):e37202 PMID: 22615941
  21. PD-1 Blockade Expands Intratumoral Memory T Cells.
    Cancer Immunol Res. 2016 Mar;4(3):194-203 PMID: 26787823
  22. Inhibition of mast cell secretion by oxidation products of natural polyamines.
    Biochem Pharmacol. 1992 May 28;43(10):2237-45 PMID: 1599509
  23. IgE-based Immunotherapy of Cancer -A Comparative Oncology Approach.
    J Carcinog Mutagen. 2014 May 31;5(3):1000176 PMID: 25264496
  24. Identification of Cancer Related Genes Using a Comprehensive Map of Human Gene Expression.
    PLoS One. 2016 Jun 20;11(6):e0157484 PMID: 27322383
  25. Dual role of macrophages in tumor growth and angiogenesis.
    J Leukoc Biol. 2006 Oct;80(4):705-13 PMID: 16864600
  26. Immune Checkpoint Inhibition in Hepatocellular Carcinoma: Basics and Ongoing Clinical Trials.
    Oncology. 2017;92 Suppl 1:50-62 PMID: 28147363
  27. Gene expression analyses reveal molecular relationships among 20 regions of the human CNS.
    Neurogenetics. 2006 May;7(2):67-80 PMID: 16572319
  28. Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability.
    Immunity. 2016 Mar 15;44(3):698-711 PMID: 26982367
  29. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma.
    Cancer Res. 2009 Sep 15;69(18):7385-92 PMID: 19723656
  30. Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.
    Clin Cancer Res. 2017 Sep 1;23 (17 ):5024-5033 PMID: 28512174
  31. Parallel patterns of evolution in the genomes and transcriptomes of humans and chimpanzees.
    Science. 2005 Sep 16;309(5742):1850-4 PMID: 16141373
  32. Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy.
    Genome Biol. 2015 Mar 31;16:64 PMID: 25853550
  33. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.
    Hepatology. 2015 May;61(5):1591-602 PMID: 25529917
  34. Global cancer statistics.
    CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90 PMID: 21296855
  35. Advances in targeted therapies for hepatocellular carcinoma in the genomic era.
    Nat Rev Clin Oncol. 2015 Jul;12(7):408-24 PMID: 26054909
  36. Prognostic value of immunoscore to identify mortality outcomes in adults with HBV-related primary hepatocellular carcinoma.
    Medicine (Baltimore). 2017 Apr;96(17 ):e6735 PMID: 28445292
  37. Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions.
    Hepatology. 2014 Nov;60(5):1776-82 PMID: 24912948
  38. Robust enumeration of cell subsets from tissue expression profiles.
    Nat Methods. 2015 May;12(5):453-7 PMID: 25822800
Article Info
Journal
Scientific reports
Abbr.
Sci Rep
ISSN
2045-2322
Published
2018-00-18
Epub
2018-00-18
Pages
6220
Language
English
Region
England
NLM ID
101563288
PMCID
PMC5906687
Subset
IM
Grants
Austrian Science Fund FWF · P 29222 · Austria
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com